Skip to main content
SpringerLink
Log in

Recent Clinical Trials in Atrial Fibrillation in Hypertensive Patients

  • The Therapeutic Trials (G Mancia and TD Giles, Section Editors)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Atrial Fibrillation (AF) is the most common clinically significant sustained cardiac arrhythmia, and Hypertension (HTN) is the most common cardiovascular disorder. AF is a major risk factor for strokes whether it is symptomatic or silent. Recent publications have shed light on the role of antihypertensive regiments in prevention of AF, while others have provided data on the efficacy and safety of novel antiarrhythmic drugs such as dronedarone and vernakalant. The older CHADS2 score and its more refined modern counterparts are well validated to determine stroke risk and guide antithrombotic therapy, but haemorrhagic risk has to be respected as well, and scores such as HAS-BLED should be widely used. Novel classes of anticoagulants that overcome many of the drawbacks of warfarin have been introduced with promising results and pose new questions that need to be answered in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370–5.

    Article  PubMed  CAS  Google Scholar 

  2. Wattigney WA, Mensah GA, Croft JB, et al. Increasing trends in hospitalization for atrial fibrillation in the USA, 1985 through 1999; implications for primary prevention. Circulation. 2003;108:711–6.

    Article  PubMed  Google Scholar 

  3. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840–4.

    Article  PubMed  CAS  Google Scholar 

  4. •• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. Major II inhibitor Dabigatran publication presenting the results of the RELY trial.

    Article  PubMed  CAS  Google Scholar 

  5. •• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. Major Xa inhibitor rivaroxaban publication presenting the results of the ROCKET AF trial.

    Article  PubMed  CAS  Google Scholar 

  6. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17.

    Article  PubMed  CAS  Google Scholar 

  7. •• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. Major Xa inhibitor apixaban publication presenting the results of the ARISTOTLE trial.

    Article  PubMed  CAS  Google Scholar 

  8. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–52.

    Article  PubMed  CAS  Google Scholar 

  9. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.

    Article  PubMed  CAS  Google Scholar 

  10. Go AS. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. Am J Geriatr Cardiol. 2005;14:56–61.

    Article  PubMed  Google Scholar 

  11. Penado S, Cano M, Acha O, et al. Atrial fibrillation as a risk factor for stroke recurrence. Am J Med. 2003;114:206–10.

    Article  PubMed  Google Scholar 

  12. Bunch TJ, Weiss JP, Crandall BG, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer’s dementia. Hear Rhythm. 2010;7:433–7.

    Article  Google Scholar 

  13. Savelieva I, Camm AJ. Silent atrial fibrillation–another Pandora’s box. Pacing Clin Electrophysiol. 2000;23:145–8.

    Article  PubMed  CAS  Google Scholar 

  14. Page RL, Tilsch TW, et al. Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or ‘silent’ atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation. 2003;107:1141–5.

    Article  PubMed  Google Scholar 

  15. •• Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke N. Engl J Med. 2012;366:120–9. Results of the ASSERT study highlighting the significance of silent or subclinical AF revealed in patients with pacemakers.

    Article  CAS  Google Scholar 

  16. Schnabel RB, Aspelund T, Li G, et al. Validation of an atrial fibrillation risk algorithm in whites and African Americans. Arch Intern Med. 2010;170:1909–17.

    Article  PubMed  Google Scholar 

  17. Mant J, Fitzmaurice DA, Hobbs FD, et al. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ. 2007;335:380.

    Article  PubMed  Google Scholar 

  18. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a metaanalysis. J Am Coll Cardiol. 2005;45:1832–9.

    Article  PubMed  CAS  Google Scholar 

  19. Kalus JS, Coleman CI, White CM. The impact of suppressing the renin angiotensin system on atrial fibrillation. J Clin Pharmacol. 2006;46:21–8.

    Article  PubMed  CAS  Google Scholar 

  20. • Schneider MP, Hua TA, Bohm M, et al. Prevention of atrial fibrillation by renin-angiotensin system-inhibition a meta-analysis. J Am Coll Cardiol. 2010;55:2299–307. RAS system inhibition efficacy in AF prevention.

    Article  PubMed  Google Scholar 

  21. Schmieder RE, Kjeldsen SE, Julius S, et al. VALUE Trial Group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26:403–11.

    Article  PubMed  CAS  Google Scholar 

  22. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712–9.

    Article  PubMed  CAS  Google Scholar 

  23. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.

    Article  PubMed  CAS  Google Scholar 

  24. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174–83.

    Article  PubMed  CAS  Google Scholar 

  25. Yusuf S, Diener HC, Sacco RL, PRoFESS Study Group, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225–37.

    Article  PubMed  CAS  Google Scholar 

  26. Tveit A, Seljeflot I, Grundvold I, et al. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol. 2007;99:1544–8.

    Article  PubMed  CAS  Google Scholar 

  27. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606–17.

    Article  PubMed  Google Scholar 

  28. Goette A, Schön N, Kirchhof P, et al. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial. Circ Arrhythm Electrophysiol. 2012;5:43–51.

    Article  PubMed  Google Scholar 

  29. Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J. 2007;28:457–62.

    Article  PubMed  CAS  Google Scholar 

  30. Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med. 2010;152:78–84.

    PubMed  Google Scholar 

  31. L'Allier PL, Ducharme A, Keller PF, et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol. 2004;44:159–64.

    Article  PubMed  Google Scholar 

  32. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.

    Article  PubMed  CAS  Google Scholar 

  33. Kowey PR, Dorian P, Mitchell LB, for the Atrial Arrhythmia Conversion Trial Investigators, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2:652–9.

    Article  PubMed  Google Scholar 

  34. • Camm AJ, Capucci A, Hohnloser SH, on behalf of the AVRO Investigators, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57:313–21. Study of Vernakalant vs Amiodarone showing enhanced efficacy of the new drug versus the current standard of care.

    Article  PubMed  Google Scholar 

  35. •• EHRA,EACTS, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–429. Current ESC AF guidelines.

    Article  PubMed  Google Scholar 

  36. • Connolly SJ, Camm AJ, Halperin JL, PALLAS Investigators, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268–76. The PALLAS study that raised serious points concerning the safety of Dronedarone and was prematurely terminated for these reasons.

    Article  PubMed  CAS  Google Scholar 

  37. •• Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363–73. A very important study highlighting the value of less strict rate control in AF.

    Article  PubMed  Google Scholar 

  38. The AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.

    Article  Google Scholar 

  39. Saksena S, Slee A, Waldo AL, et al. Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J Am Coll Cardiol. 2011;58:1975–85.

    Article  PubMed  CAS  Google Scholar 

  40. Bunch TJ, Crandall BG, Weiss JP, et al. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22:839–45.

    Article  PubMed  Google Scholar 

  41. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41:2731–8.

    Article  PubMed  CAS  Google Scholar 

  42. •• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100. The first publication of the HAS BLED score which since has become the standard of care for AF patients and a guideline – endorsed practice.

    Article  PubMed  Google Scholar 

  43. Piazza G, Nguyen TN, Cios D, et al. Anticoagulation-associated adverse drug events. Am J Med. 2011;124(12):1136–42.

    Article  PubMed  CAS  Google Scholar 

  44. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638–45.

    Article  PubMed  CAS  Google Scholar 

  45. Lee S, Shafe ACE, Cowie MR. UK stroke incidence, mortality and cardiovascular risk management 1999-2008: time-trend analysis from the General Practice Research Database. BMJ Open. 2011;1:e000269. doi:10.1136/bmjopen-2011-000269.

    Article  PubMed  Google Scholar 

  46. •• Wann LS, Curtis AB, Ellenbogen KA, et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:1144–50. The first recommendation on the use of non VKA anticoagulants for AF.

    Article  PubMed  Google Scholar 

  47. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562–70.

    Article  PubMed  Google Scholar 

  48. • Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397–402. Is there an increased risk of acute coronary events by the use of Dabigatran?

  49. • Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012;125:669–76. Is there an increased risk of acute coronary events by the use of Dabigatran?

  50. • Mega JL, Braunwald E, Wiviott SD, ATLAS ACS 2–TIMI 51 Investigators, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19. A positive result study on the efficacy of rivaroxaban in Acute Coronary Syndromes.

    Article  PubMed  CAS  Google Scholar 

  51. Alexander JH, Lopes RD, James S, APPRAISE-2 Investigators, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699–708.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosures

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Cardiology, Asklepeion General Hospital, 1, Vassileos Pavlou St, Voula, Athens, 16673, Greece

    Athanasios J. Manolis, Manolis S. Kallistratos & Leonidas E. Poulimenos

Authors
  1. Athanasios J. Manolis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manolis S. Kallistratos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leonidas E. Poulimenos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Athanasios J. Manolis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Manolis, A.J., Kallistratos, M.S. & Poulimenos, L.E. Recent Clinical Trials in Atrial Fibrillation in Hypertensive Patients. Curr Hypertens Rep 14, 350–359 (2012). https://doi.org/10.1007/s11906-012-0268-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-012-0268-5

Keywords

Search

Navigation